Association between ICAM-1 level and diabetic retinopathy: a review and meta-analysis. Issue 1121 (20th May 2019)

• Record Type: Journal Article
• Authors: Yao, Yang; Du, Junhui; Li, Rong; Zhao, Lei; Luo, Na; Zhai, Jing Ya; Long, Lihui
• Is Part Of: Postgraduate medical journal. Volume 95:Issue 1121(2019)
• Page Start: 162
• Page End: 168
• Publication Date: 2019-05-20
• Subjects: intercellular adhesion molecule-1 -- diabetic retinopathy -- meta-analysis -- inflammation -- celladhesion molecules; Medicine -- Periodicals; 610
• DOI: 10.1136/postgradmedj-2018-136102
• Languages: English
• ISSNs: 0032-5473

Abstract

Abstract: Elevated levels of proinflammatory markers are evident in patients with diabetic retinopathy (DR) and are associated with disease progression and prognosis. Intercellular adhesion molecule-1 (ICAM-1) is involved in inflammation and acts as a local intensifying signal in the pathological processes associated with chronic eye inflammation. The aim of this systematic review and meta-analysis was to investigate the relationship between ICAM-1 level and DR. Online electronic databases were searched to retrieve all relevant articles published before December 2017. The standard mean difference (SMD) and their 95% CI were included and then pooled with a random effects model. Subgroup analysis and metaregression analysis were applied to explore the sources of heterogeneity, and publication bias was calculated to assess the quality of pooled studies. A total of 11 articles, containing 428 patients with DR and 789 healthy controls, were included in this meta-analysis. The results indicated a significant increase in ICAM-1 level in the DR group compared with the control group (SMD: 1.20, 95%CI 0.83 to 1.57, p<0.001). Subgroup analyses and metaregression analysis indicated that publication year, region, study method, diabetes mellitus type, Newcastle-Ottawa Scale and sample size were not the potential sources of heterogeneity. The results of this current meta-analysis indicated that the increased level of ICAM-1 generally exists in the patients with DR and it may associated with the severity of DR. However, large-scale and high-quality studies are required to confirm this finding in the future.